Discover

BIO
Bio-Rad Laboratories, Inc.
301.70
1 x 291.11
1 x 311.12
bid
ask
-
0.20
0.07%
04:00 PM
Ytd-0.43%
1y23.52%
285.39
day range
302.93
236.73
52 week range
343.12
Open290.50Prev Close301.90Low285.39High302.93Mkt Cap8.16B
Vol302.88KAvg Vol388.28KEPS9.27P/E32.55Forward P/E34.36
Beta1.08Short Ratio3.09Inst. Own94.35%DividendN/ADiv YieldN/A
Ex Div DateN/AEarning07-3050-d Avg288.73200-d Avg294.931yr Est297.00
Earning
DateForEstimateReportedSurprisesurprise %
2026-07-302026-061.75N/AN/AN/A
2026-04-302026-031.971.89-0.08-4.06%
2026-02-122025-122.572.51-0.06-2.33%
2025-10-292025-092.32.26-0.04-1.74%
2025-07-312025-061.932.610.6835.23%
2025-05-012025-031.732.540.8146.82%
Upgrade / Downgrade
DateFirmActionFromTo
2026-05-01Wells FargoUpgradeEqual-WeightEqual-Weight
2026-04-07CitigroupDowngradeBuyNeutral
2026-02-16Wells FargoUpgradeEqual-WeightEqual-Weight
2025-10-30CitigroupUpgradeBuyBuy
2025-10-30Wells FargoUpgradeEqual-WeightEqual-Weight
2025-08-01RBC CapitalUpgradeOutperformOutperform
Profile
Bio-Rad Laboratories, Inc., established in 1952 and headquartered in Hercules, California, operates as a global provider of life science research and clinical diagnostic products. Its operations span across the United States, Canada, Europe, Asia, and Latin America. The company is organized into two primary divisions: Life Science and Clinical Diagnostics. The Life Science division is responsible for developing, manufacturing, and commercializing a diverse array of reagents, equipment, and laboratory instruments. These products are crucial for various research methodologies, biopharmaceutical manufacturing processes, and food quality testing. This segment focuses on specialized areas within the life sciences, including proteomics, genomics, biopharmaceutical production, cellular biology, and food safety. Its clientele encompasses academic institutions (such as universities and medical schools), industrial research organizations, government agencies, pharmaceutical companies, biotechnology firms, food producers, and food testing laboratories. In contrast, the Clinical Diagnostics division designs, produces, sells, and supports a comprehensive suite of test systems, informatics solutions, diagnostic kits, and specialized quality control products for clinical laboratories. This segment provides reagents, instruments, and software specifically tailored for particular niches within the in vitro diagnostics market. Its customer base includes reference laboratories, hospital laboratories, state newborn screening facilities, physicians' office laboratories, and transfusion laboratories. Beyond these core segments, Bio-Rad also offers systems and products designed to separate complex chemical and biological materials, as well as to identify, analyze, and purify their individual components. The company distributes its extensive product portfolio through a combination of its direct sales force and a network of third-party distributors, agents, brokers, and resellers.
Insider Holder
DateNameRelationQuantityDescription
2025-09-04ALLISON SCHWARTZDirector1.46KConversion of Exercise of derivative security
2025-09-04COREY COLLEENOfficer19.55KConversion of Exercise of derivative security
2025-03-13CROWLEY MICHAEL WOfficer8.17KConversion of Exercise of derivative security
2025-10-23DIVINCENZO JONATHAN PPresident919.00Conversion of Exercise of derivative security
2025-10-19EVRAN SEDATOfficer2.23KConversion of Exercise of derivative security
2026-04-20HINCKLEY GREGORY KDirector1.22KConversion of Exercise of derivative security
Institution Ownership
Report DateOrganizationPositionValuePercentage
2026-03-30Arnhold & S. Bleichroeder Advisers, LLC2.60M0.009.73%
2025-12-30Vanguard Group Inc1.77M0.006.63%
2026-03-30BlackRock Inc1.68M0.006.28%
2026-03-30Dimensional Fund Advisors, Inc.1.09M0.004.07%
2026-03-30Vanguard Capital Management, LLC831.17K0.003.11%
2026-03-30Vanguard Portfolio Management, LLC829.19K0.003.10%
Fund Ownership
Report DateOrganizationPositionValuePercentage
2026-06-29First Eagle Global A1.88M0.007.02%
2026-03-30UBS: Global Equity1.27M0.004.74%
2026-03-30American Funds SMALLCAP World A756.04K0.002.83%
2026-06-29iShares Core S&P Mid-Cap ETF613.08K0.002.29%
2026-06-29Vanguard Total Stock Mkt Idx Inv584.89K0.002.19%
2026-06-29Vanguard Small Cap Index423.31K0.001.58%
Split
SplitDate
2 : 12002-03-08
3 : 21996-06-03
3 : 21986-06-11
1 : 11986-06-10
3 : 21985-08-01
1 : 11985-07-31